Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC + Toripalimab in Advanced HER2+ Scrotal Extramammary Paget Disease
NCT06791070Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in extramammary Paget disease (EMPD), sponsored by Fujian Medical University Union Hospital. Started Jan 2025; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on NCT06791070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06791070.